Bio
Dr Lirlândia (Landa) Sousa graduated in Pharmacy-Biochemistry at the Federal University of Ouro Preto (1995) and received her Master's (1998) and Ph.D. degree in Microbiology from the Federal University of Minas Gerais (2003). She then worked as a postdoctoral fellow at the Immunopharmacology Lab (UFMG) from 2004 to 2007. Dr Sousa was a visiting professor at the Department of Cell and Molecular Biology in the lab of Prof Lindsey Miles in The Scripps Research Institute, San Diego from 2017 to 2018. Currently, Dr Landa Sousa is an Associate Professor at the Faculty of Pharmacy at UFMG. She supervises graduate and post-graduate students at the post-graduate programs in Clinical and Toxicological Analysis and Pharmaceuticals Sciences.

Bio
Dr Stefano Bruscoli completed his undergraduate studies at the University of Perugia, Italy, and he gained a Ph.D. in Immunological Sciences in 2003 from University ‘La Sapienza’ in Rome, Italy. During his Ph.D., part of the research activity was conducted at the Institute of Cancer Genetics, Columbia University, NY, USA, focused on analysing genetic alterations associated with chronic B-cell leukaemia. After a period as a Post-Doc Research Fellow, studying the molecular mechanisms (genomic and non-genomic effects) of action of glucocorticoids (GCs) in T lymphocytes, in 2006 he became an Assistant Professor of Pharmacology at the Department of Clinical and Experimental Medicine, University of Perugia, where he continued to investigate the anti-inflammatory and immunomodulatory effects of GCs. Dr Bruscoli is now an Associate Professor of Pharmacology at the Department of Medicine, University of Perugia, Italy. Dr Bruscoli’s research mainly focuses on characterising the biological activities of the GC-induced gene Glucocorticoid-Induced Leucine Zipper (GILZ), which acts as an effector of GC-induced processes in many cell and disease contexts. Most of his studies involve in vivo animal models using GILZ knockout and transgenic GILZ-overexpressing mice. In his research, the molecular mechanisms of the anti-inflammatory and immunosuppressive effects of GILZ are investigated using various experimental models of inflammatory and autoimmune diseases (i.e., colitis, arthritis, spinal trauma, experimental autoimmune encephalomyelitis, and different fibrotic models).

Bio
Graduated in Pharmacy, Dr Sugimoto earned her M.Res. in 2014 and Ph.D. in 2018 from the Federal University of Minas Gerais in Brazil. Following a postdoctoral fellowship in the laboratory of Professor Mauro Teixeira in Brazil, she joined University College London, where she is now an Academy of Medical Sciences Newton International Fellow. Her research explores the inflammation resolution pathways that can be harnessed to treat diseases with a significant inflammatory component. In 2019, Dr Sugimoto was awarded the CAPES Thesis Award for the identification of an unprecedented relationship between the fibrinolytic system and the resolution of inflammation, highlighting the interlocution between systems previously considered independent.

Bio
Professor Perretti is the dean for Research and Research Impact (2015–) and Professor of Immunopharmacology (2001–) at William Harvey Research Institute, Barts and The London School of Medicine and Dentistry. Professor Perretti pioneered the field of ‘Resolution of Inflammation’ as an area of biology that defines the endogenous mechanisms, mediators, and receptors operative to temper over-shooting inflammation and enable tissue protection or repair. He has a strong interest in translating this biology into innovative therapeutic approaches by assessing the science required to develop agonists at pro-resolving receptors. His long term aim is to establish resolution pharmacology as a novel branch of the discipline. Prof Perretti has authored more than 400 publications in inflammation and resolution, having more than 33,000 citations.